Engineered immune cells take on stomach cancer in early trial
NCT ID NCT07551362
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment using specially designed immune cells (CAR-NK cells) that target two proteins found on stomach cancer cells. The therapy is given to adults with advanced stomach or gastroesophageal junction cancer that has not responded to standard treatments. The goal is to see if it is safe and can shrink tumors, but patients may need ongoing care to manage the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Shenzhen Hospital
RECRUITINGShenzhen, Guangdong, 518036, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental drug combo targets Hard-to-Treat GI cancers
- New drug cocktail aims to tackle Hard-to-Treat stomach cancer
- New drug duo takes aim at hard-to-treat stomach cancer with liver metastases
- New drug cocktail aims to fight tough stomach cancer
- New pill combo aims to fight stomach cancer when first treatment fails
- Stomach cancer hope: new combo targets tumors after PD-1 failure